Immuno-oncology (IO) treatment in first-line metastatic non-small cell lung carcinoma (mNSCLC) – a focus on KEYTRUDA (pembrolizumab) in patients with a PD-L1 expression of <1% through case studies (Case study 2/3)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
This series of bite sized peer-to-peer videos by experienced clinical nurse specialists, specialist registrars and oncologists has been created to share their knowledge and experience of the day-to-day management of patients with mNSCLC treated with KEYTRUDA plus chemotherapy.
Licensed indications in mNSCLC
- KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations
- KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations
- KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous non-small cell lung carcinoma in adults
- KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA
This module is CPD certified, offering a certificate upon completion.
Introduction
Please use the tabs below to navigate through this case study, please note you must complete all 3 case studies to receive the CPD certificate.
Upon watching all videos there are some questions for you to reflect on, which should take around 20 minutes.
We estimate the 3 case studies will take roughly an hour to complete, and upon completion (if logged in) a CPD certificate will become available and can be downloaded by clicking the final navigation tab on the last video. This certificate will also be sent to you via email to download.
-
Patient
introduction -
The clinical
data -
Patient journey
from time of
relapse through
to post treatment -
Adverse
events -
Patient journey
during maintenance
therapy and then
coming off treatment
Related content
References
- KEYTRUDA Summary of Product Characteristics.
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.
